Medtronic Announces FDA Approval for Cardiac Resynchronization Therapies (MDT)

Medtronic, Inc. MDT today announced the U.S. Food and Drug Administration approval and launch of the Attain Ability Plus and the Attain Ability® Straight left-heart leads for use with cardiac resynchronization therapy devices in treating heart failure patients. The two new dual-electrode leads are the latest offering in a line of advanced left-heart lead options that fit through the Attain Select® II sub-selection catheter delivery system and navigate a variety of patient vein anatomies to enhance success during the CRT implant procedure.